• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Global Blood Plasma Market Report: 2013 Edition- Koncept Analytics
 

Global Blood Plasma Market Report: 2013 Edition- Koncept Analytics

on

  • 879 views

Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around ...

Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.

With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail.

Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.

Statistics

Views

Total Views
879
Views on SlideShare
879
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Global Blood Plasma Market Report: 2013 Edition- Koncept Analytics Global Blood Plasma Market Report: 2013 Edition- Koncept Analytics Presentation Transcript

    • View Report Details Global Blood Plasma Market------------------------------------------- 2013
    • View Report DetailsExecutive SummaryPlasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioningof the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma initself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, andimmunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeuticvalues. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.With the swift progression in the field of biomedical/healthcare technology, companies operating in thehealthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of theescalating incidences of health related issues originating due to changing lifestyle and continuously changingsurroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blooddisorders, autoimmune diseases and liver function impairment among others, associated companies are coming up withnovel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market ischaracterized by fast pace developments in the clinical technology and testing methodology. This report elicits the globalblood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regionsincluding the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growthdrivers and challenges are analyzed in detail.Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasmamarket is quite fierce with numerous local and global players contenting for the market share. On the global front, the keyplayers are Baxter, CSL, Grifols and Octapharma.
    • The normal composition of human blood is: Plasma, Red Blood Cells (RBC), White Blood Cells (WBC) and Platelets… Global Blood Plasma Market (2000-2011) The global blood plasma market was valued at US$.......billion in 2010, and reached US$....... billion in 2011, depicting an increase of ……….% approximately. The recorded CAGR over the cited 2011 period was …….%. 2010 In terms of products, in 2011, the global blood plasma market 2009 was dominated by IVIGs or IGs with a significant share of ……..% 2008 followed by FVIII with …….% share. FIX and albumin constituted 2007 ……% share each. 2006 2005 The plasma derivatives sales in the US stood at US$....... billion 2004 in 2011, witnessing an increase of …..% approximately over the 2003 value of US$......... billion in 2010. 2002 The manufacturing cost structure of plasma fractionation is such 2001 that the major portion of the cost, approximately …..%, is 2000 constituted by plasma product. US$ Billion Plasma Derivative Sales in the US (2005-2011) Global Plasma Market Share by Product (2011) US$ Billion 2005 2006 2007 2008 2009 2010 2011 IG Factor VIII Factor IX Albumin Other Products
    • Plasma is the raw material for the extraction of various proteins. It can be divided into two categories depending on how it is obtained viz. Source plasma and Recovered plasma... Global IVIG Market Size (2004-2011)  As of 2011, the global sales of immunoglobulins stood at US$...... billion, registering a modest growth of …….% over the value of 2010. For the period of 7 years spanning from 2004 to 2011, the global IVIG market recorded an impressive CAGR of …………%.  In terms of IVIG market size by volume, the US accounted for the maximum share with ……..tonnes of IVIG, followed by the EU withUS$ Billion ……….tonnes of contribution in the global IVIG market as of 2011. In terms of value, the U.S. market was worth ……..billion approximately in 2011.  The IVIG market in the US stood at US$............billion in 2011, recording an increase of nearly ……..% over US$......... billion worth sales generated in 2010. The CAGR recorded over the cited period was ……..%. 2004 2005 2006 2007 2008 2009 2010 2011 Sales of IVIG in the US (2001-2011) IVIG Market Volume by Region (2005, 2008 and 2011) ) US$ Billion Tonnes 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2005 2008 2011 USA EU RoW
    • In frozen condition, plasma can keep for up to 10 years, making it an extremely stable blood product. Also, it can be packaged in dried form for reconstitution… Global Plasma Market Share by Company (2011) Global Hemophilia Treatment Market Revenues (2006-2012)201220112010200920082007 Grifols CSL2006 Baxter Octapharma Others- for profit Others- for non profit US$ Billion Albumin Market Size of the US and China The global hemophilia treatment market revenues has been moving on an aggressive growth path, registering an increase of US$........billion to US$........billion by 2012 as compared to US$............ billion in 2006. As of October 2012, the albumin market of China was worth US$……. million while the same in the US was worth US$........million only. As of 2011, the global plasma market was led by Grifols with 20% share, US$ Million followed by CSL and Baxter with shares worth ……% and …..%, respectively. Octapharma accounted for ………% share in the same. The opportunity for global blood plasma market is anticipated to be US$...... billion for the year 2012. The respective market is poised to record a growth of ……% in 2012 as compared to the value of US$.......billion in 2011. The global blood plasma market is projected to grow at a CAGR of …….% over the period of three years spanning from 2012 to 2015 and estimated to reach US$.......... billion by the end of 2015. USA China Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
    • Table of Contents List of Charts & Tables 1. Overview List of Charts 1.1 Components of Blood Plasma Plasma Extraction from Donated Blood (Recovered Plasma) 1.2 Functions of Blood Plasma Plasmapheresis (Source Plasma) 1.3 Collection and Extraction of Plasma Global Blood Plasma Market (2000-2011) Global Plasma Market Share by Product (2011) 1.3.1 Plasma Collection Manufacturing Cost Split for Plasma Fractionation (September 2011) 1.3.2 Plasma Extraction Plasma Derivative Sales in the US (2005-2011) 1.3.3 Plasma Fractionation Yield US Source Plasma Collections (2007-2012E) 1.3.4 Plasma Usage Global IVIG Market Size (2004-2011) Global IVIG Demand and Supply (2007-2012E) 2. Blood Plasma Market Structure IVIG Market Volume by Region (2005, 2008 and 2011) Global IVIG Market Share by Geography (2011) 2.1 Global Blood Plasma Market IVIG Use by Indication -Market Value Sales of IVIG in the US (2001-2011) -Market Segments Global Hemophilia Treatment Market Revenues (2006-2012) Global FVIII Market (2011) 2.1.1 Plasma Industry Cost Structure Global FIX Market (2011) 2.1.2 Plasma Market of the US Annual Global Sales of NovoSeven (2007-2011) Monthly Distribution of FVIII in the US (January 2011-September 2012) 2.2 Global IVIG Market Albumin Market Size of the US and China -Market Value Albumin Price across US and China -Demand & Supply China’s Plasma Protein Market Growth (October 2012) -Breakdown by Region Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012) 2.2.1 IVIG Market of the US Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012) 2.3 Global Hemophilia Market Licensed Plasma Centers in the US and their profitability (FY06-FY11) -Hemophilia A A1PI Statistics of North America and EU -Hemophilia B Per Capita Usage of FVIII in Developed Countries Per Capita Usage of FVIII in Developing Countries 2.3.1 FVIII Market of the US Per Capita FIX Usage in Developed Economies Per Capita FIX Usage in Emerging Economies 2.4 Albumin Market Global Healthcare Spending (2005-2015E) Global Spending on Medicines (2006-2016E) 2.4.1 Albumin Market of China and the US Global Spending on Medicine Share by Region (2006-2016E) 3. Market Dynamics 3.1 Key Trends
    • 3.1.1 Kinetics of Plasma-collection Industry List of Charts3.1.2 Reimbursement3.1.3 Growing Penetration of rFVIII Products in Emerging Markets The US Spending on Medicine (2007-2016E)– Opportunity for Manufacturers Japan’s Spending on Medicine (2007-2016E)3.1.4 A1PI Deficiency- Confined to Prevention only Biotechnology Therapeutics Under Development (2011) Global Ageing Population (2005-2013F)3.2 Industry Developments Global Male Population (2005-2014F) Global GDP (2001-2011)3.2.1 Improved Biological Molecule Formulations World GDP per Capita (2005-2011)3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A Global Plasma Market Share by Company (2011) Aligned PCCs vs. independent PCCs Share in the US (2011)3.3 Growth Drivers Europe’s IVIG Market Share (2011) North America’s IVIG Market Share (2011)3.3.1 Increasing New Patient Registration for Hemophilia US IVIG Market (2011)Treatment US Albumin Market Share (2011)3.3.2 Increased Usage of Plasma Derived Products China’s Albumin Market (2011-12)3.3.3 Rising Healthcare Expenditure Product Rivalry in the US (2011)3.3.4 Higher Spending on Medicines Baxter’s Revenue by Business Segments (2011)3.3.5 Rising Demand for Better Healthcare Options Baxter’s Revenues and Net Income (2008-2011)3.3.6 Launch of NMEs (New Molecular Entities) Grifols Revenue Share by Business Segments (2011)3.3.7 Growing Ageing Population (+60 Years) Grifols’ Revenues & Profits (2008-2011)3.3.8 Rising Male Population CSL’s Revenue Share by Major Products (2011-12)3.3.9 Ameliorating Economic Conditions CSL’s Revenues and Net Profit (2008/09-2011/12) Octapharma’s Net Sales and Net Profit (2008-2011)3.4 Challenges Global Blood Plasma Market Forecast (2009-2015F)3.4.1 Increasing regulation in the plasma-collection industry List of Tables3.4.2 Escalating Price Pressure3.4.3 Constrained Plasma Fractionation Capacity Constituents of Blood Plasma3.4.4 Misdiagnosis of the Disease Recovered plasma vs. Source plasma Output per Liter of Plasma4. Competitive Landscape Breakdown of US IVIG usage by Patient Share & Volume Share by Indication Breakdown of US SCIG and IVIG Usage by Volume Share (FY11)4.1 Blood Plasma Market Rivalry US Centre for Medicare and Medicaid (CMS) Reimbursement4.2 Plasma Derivatives Market Contention Conversion to Recombinant Factor VIII Products in Selected Countries (2010) A1PI Products4.2.1 Immunoglobulins Long Acting FIX & FVIII under Late-Stage Development-IVIG Market of Europe-IVIG Market of North America-IVIG Market of the US4.2.2 Albumin Market-Albumin Market of the US
    • -Albumin Market of China List of Tables4.2.3 Other Products Extended Half Life rFVIII Agents5. Company Profiles Extended Half Life rFIX Agents New Patient Registrations in Worldwide Bleeding Disorders Market (2008-5.1 Baxter International Inc. 2013E)5.1.1 Business Overview Patients Worldwide Waiting for Better Treatment Options (2011)5.1.2 Financial Overview Global Availability of NMEs (2011)5.1.3 Business Strategies IVIG Product Characteristics-Focus on Investment in R&D Dependent & Independent Variables (2007-2011)-Growth through Sustainable Development Correlation Matrix Regression Coefficients Output5.2 Grifols5.2.1 Business Overview5.2.2 Financial Overview5.2.3 Business Strategies-Expansion in Other Geographic Regions-Growth through Mergers and Acquisitions5.3 CSL Limited5.3.1 Business Overview5.3.2 Financial Overview5.3.3 Business Strategies-Focus on R&D-Expanding Product Portfolio5.4 Octapharma5.4.1 Business Overview5.4.2 Financial Overview5.4.3 Business Strategies-Focus on Innovation-Expansion of Production Facilities6. Market Outlook6.1 Market Forecast6.2 Forecast Methodology6.2.1 Dependent and Independent Variables6.2.2 Correlation Analysis6.2.3 Regression Analysis
    • Contact Us: View Report DetailsThese are abridged and sanitized sample pages from the comprehensive report on the “Global Blood Plasma Market”. To knowmore about this report or for any customized research requirement, please contact the following: Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 Vikas Gupta T. +91-120-4130959 BD Manager C: +91-9811715635 vikas@konceptanalytics.com www.konceptanalytics.com